论文部分内容阅读
目的探讨沙利度胺联合柳氮磺吡啶治疗强直性脊柱炎(AS)的疗效及对复发的影响。方法 39例强直性脊柱炎患者,所有患者均给予沙利度胺联合柳氮磺吡啶治疗,观察治疗前后患者的各项检测指标改善情况,通过随访记录患者复发情况。结果治疗后患者的AS活动指数(BASDAI)、AS功能指数(BASFI)、晨僵时间、扩胸度、指地距、枕壁距及Schober试验结果较治疗前均有改善,差异有统计学意义(P<0.05)。治疗过程中仅3例患者出现轻微不良反应,不良反应发生率为7.7%,随访结果发现1例患者复发,复发率为2.6%。结论沙利度胺联合柳氮磺吡啶治疗强直性脊柱炎不仅能提高临床治疗效果,还能够降低复发率,是一种可靠的临床治疗方案。
Objective To investigate the efficacy and safety of thalidomide combined with sulfasalazine for the treatment of ankylosing spondylitis (AS). Methods Thirty-nine patients with ankylosing spondylitis were treated with thalidomide combined with sulfasalazine. The improvement of each test index was observed before and after treatment. The recurrence was recorded by follow-up. Results After treatment, ASDA (BASDAI), ASFI (BASFI), morning stiffness, chest enlargement, anteroposterior distance, pillow wall distance and Schober test results were significantly improved compared with before treatment, the difference was statistically significant (P <0.05). In the course of treatment, only 3 patients showed mild adverse reactions, the incidence of adverse reactions was 7.7%. Follow-up results showed that 1 patient recurred with a recurrence rate of 2.6%. Conclusion Thalidomide combined with sulfasalazine in the treatment of ankylosing spondylitis not only can improve the clinical curative effect, but also reduce the recurrence rate, which is a reliable clinical treatment plan.